When attached to supporting electronics, the sensor can wirelessly transmit data to the user’s cell phone through Bluetooth.
CREDIT: Caltech
One feature of the COVID-19 virus that makes it so difficult to contain is that it can be easily spread to others by a person who has yet to show any signs of infection. The carrier of the virus might feel perfectly well and go about their daily business–taking the virus with them to work, to the home of a family member, or to public gatherings.
A crucial part of the global effort to stem the spread of the pandemic, therefore, is the development of tests that can rapidly identify infections in people who are not yet symptomatic.
Now, Caltech researchers have developed a new type of multiplexed test (a test that combines multiple kinds of data) with a low-cost sensor that may enable the at-home diagnosis of a COVID infection through rapid analysis of small volumes of saliva or blood, without the involvement of a medical professional, in less than 10 minutes.
The research was conducted in the lab of Wei Gao, assistant professor in the Andrew and Peggy Cherng department of medical engineering.. Previously, Gao and his team have developed wireless sensors that can monitor conditions such as gout, as well as stress levels, through the detection of extremely low levels of specific compounds in blood, saliva, or sweat.
Gao’s sensors are made of graphene, a sheet-like form of carbon. A plastic sheet etched with a laser generates a 3D graphene structure with tiny pores. Those pores create a large amount of surface area on the sensor, which makes it sensitive enough to detect, with high accuracy, compounds that are only present in very small amounts. In this sensor, the graphene structures are coupled with antibodies, immune system molecules that are sensitive to specific proteins, like those on the surface of a COVID virus, for example.
Previous versions of the sensor were impregnated with antibodies for the hormone cortisol, which is associated with stress, and uric acid, which at high concentrations causes gout. The new version of the sensor, which Gao has named SARS-CoV-2 RapidPlex, contains antibodies and proteins that allow it to detect the presence of the virus itself; antibodies created by the body to fight the virus; and chemical markers of inflammation, which indicate the severity of the COVID-19 infection.
“This is the only telemedicine platform I’ve seen that can give information about the infection in three types of data with a single sensor,” Gao says. “In as little as a few minutes, we can simultaneously check these levels, so we get a full picture about the infection, including early infection, immunity, and severity.”
Established COVID-testing technologies usually take hours or even days to produce results. Those technologies also require expensive, complicated equipment, whereas Gao’s system is simple and compact.
So far, the device has been tested only in the lab with a small number of blood and saliva samples obtained for medical research purposes from individuals who have tested positive or negative for COVID-19. Though preliminary results indicate that the sensor is highly accurate, a larger-scale test with real-world patients rather than laboratory samples must be performed, Gao cautions, to definitively determine its accuracy.
With the pilot study now completed, Gao next plans to test how long the sensors last with regular use, and to begin testing them with hospitalized COVID-19 patients. Following in-hospital testing, he would like to study the suitability of the tests for in-home use. Following testing, the device will need to receive regulatory approval before it is available for widespread use at home.
“Our ultimate aim really is home use,” he says. “In the following year, we plan to mail them to high-risk individuals for at-home testing. And in the future, this platform could be modified for other types of infectious disease testing at home.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
COVID-19 detector
- Factually: In Georgia, fact-checkers have become targets of the ruling party
The Georgian ruling party developed a network of pseudonymous Facebook accounts and a “fact-checking” page targeting mostly independent media outlets, civil society organizations, and more recently, ...
- Ultrasonic Flaw Detector Market Size In 2022 | No of Pages 116 | long-term Calculated Business Plan by Recognizing Shifting Trends up to 2026
Aug 04, 2022 (The Expresswire) -- "Ultrasonic Flaw Detector Market" Insights 2022 Report Contains116pages With Applications [Energy, Aerospace, Oil and ...
- For South Jersey Elevator, Business Is Going Up, But Supply Chain Shortage Means More Elevators Being Stuck In Place
A local business owner recommends building owners and landlords be transparent about the challenges with their tenants.
- Fog Detectors Market In 2022 : In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Report with Top Countries Data
Aug 02, 2022 (The Expresswire) -- "Fog Detectors Market" Insights 2022 By Types, Applications, Regions and Forecast to 2028. The global Fog Detectors ...
- GM Files To Patent Airborne Coronavirus Detection System
GM has filed a patent application for a system that could detect airborne COVID-19 and other coronavirus particles in a vehicle and sound an alarm to warn vehicle occupants of the presence of the ...
Go deeper with Google Headlines on:
COVID-19 detector
Go deeper with Bing News on:
Rapid detection of COVID-19
- FDA Grants Extension of Shelf-life & Expiration Date for GenBody COVID-19 Ag Test
GenBody America has announced that the FDA has granted an extension of the shelf-life for its COVID-19 Ag test from 12 months to 21 months ...
- Qorvo® Biotechnologies Receives FDA Emergency Use Authorization (EUA) for Rapid COVID-19 Antigen Testing at the Point of Care
Qorvo® (Nasdaq: QRVO), a leading global provider of connectivity and power solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for ...
- Scientists develop nanoparticle-based biosensing device for rapid and ultrasensitive detection of SARS-CoV-2
Researchers developed a gold nanoparticle-based biosensing device for rapid and ultrasensitive detection of SARS-CoV-2 in point-of-care settings.
- Lord's Mark Industries collaborates with Sensing Self to launch 99 per cent accuracy rate COVID-19 Saliva-based Rapid Antigen Test Kit in India
Mumbai Maharashtra [India] August 2 ANINewsVoir LordsMed the pharma division of Lord Mark Industries Pvt Ltd has entered into an Exclusive partnership with Singapore-based diagnostics kit manufacturer ...
- Lord’s Mark Industries collaborates with Sensing Self to launch COVID-19 saliva-based rapid antigen test kit in India
Under this agreement with Sensing Self, Lord’s Mark Industries will collaborate with various government agencies and authorities to offer the Covid-19 saliva-based rapid antigen kits to support ...